The US Lovenox market is currently running at $1.2-1.3B annualized, according to Rick Shea on today’s Lazard webcast; this is much higher than the $600M figure I estimated in #msg-80906388.
If Shea is correct, NVS should have little trouble maintaining quarterly Lovenox sales of at least $50M, as this would represent only 15-17% market share.
Market Data 
Markets 
AI
